BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now.
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 8,050,959 | $169,150,649 | -6% | 10.81% |
| 2. | Point72 Asset Management Steve Cohen | 4,882,053 | $102,571,934 | +15% | 0.11% |
| 3. | Eversept Partners Kamran Moghtaderi | 3,314,408 | $69,635,712 | -5% | 3.51% |
| 4. | Kingdon Capital Mark Kingdon | 2,350,000 | $49,373,500 | -6% | 5.87% |
| 5. | Hood River Capital Management David Swank | 2,316,553 | $48,670,779 | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 3,000 | $0.00 | 93,746 | 2025-05-19 | Filing | |
| $9.00 | 11,765 | $105,826.18 | 35,165 | 2025-05-16 | Filing | |
| $8.99 | 5,000 | $44,950.00 | 79,000 | 2025-05-19 | Filing | |
| $9.11 | 10,000 | $91,120.00 | 100,000 | 2025-05-19 | Filing | |
| $20.03 | 1,250 | $25,037.25 | 52,623 | 2024-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.03 | 17,159 | $360,819.45 | 491,690 | 2026-02-09 | Filing | |
| $21.03 | 3,410 | $71,705.48 | 140,429 | 2026-02-09 | Filing | |
| $20.62 | 7,412 | $152,835.44 | 508,849 | 2026-02-06 | Filing | |
| $20.62 | 2,082 | $42,930.84 | 143,839 | 2026-02-06 | Filing | |
| $16.41 | 157,307 | $2,582,021.37 | 298,661 | 2025-09-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,239,002 | $173,101,429 | 0% | |
| 2. | 6,230,334 | $130,899,317 | 0% | |
| 3. | 5,695,375 | $119,659,829 | 0.01% | |
| 4. | 4,710,746 | $98,972,773 | 0.01% | |
| 5. | 4,596,552 | $96,573,558 | 0% |
News See All
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory
We came across a bullish thesis on Syndax Pharmaceuticals, Inc. on BioEquity Watch’s Substack.
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks with huge upside potential.
10 Most Promising Stocks with Huge Upside Potential
On November 25, Matt Powers, managing partner of Powers Advisory Group, joined CNBC's 'Squawk Box' to discuss what to make of recent volatility and why he believes that value will start to pick up.
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating
On November 12, 2025, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) saw JPMorgan reduce its price target from $40 to $33, while reiterating its “Overweight” rating.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Third Quarter 2025 Earnings Conference Call. Today's call is being recorded.
Syndax's Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20.
10 Best Stocks to Buy Under $20
On September 16, Ali Dibadj, Janus Henderson Investors CEO, joined 'Squawk Box' on CNBC to discuss the latest market trends and suggest that small and mid-cap stocks have enormous potential to deliver...
Hedge Fund Resource Center